Skip to main content

Nasdaq IPOs

Tech-focused SPAC Falcon Peak Acquisition withdraws $250 million IPO

5 years 2 months ago
Falcon Peak Acquisition, a blank check company formed by TI Capital and Falcon Peak targeting tech-driven businesses, withdrew its plans for an initial public offering on Friday. It had filed to raise $250 million by offering 25 million units at $10.The New York, NY-based company
Renaissance Capital

Tech SPAC Belong Acquisition prices $150 million IPO

5 years 2 months ago
Belong Acquisition, a blank check company targeting high-growth tech and tech-enabled businesses, raised $150 million by offering 15 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50.The company is led by&n
Renaissance Capital

Miami community bank U.S. Century Bank prices IPO at $10 low end

5 years 2 months ago
U.S. Century Bank, a community bank in the Miami-Dade MSA, raised $40 million by offering 4 million shares at $10, the low end of the range of $10 to $12.50. U.S. Century has 11 banking centers and a digital banking platform, offering a range of commercial products and services f
Renaissance Capital

Content marketing platform Outbrain prices IPO below the range at $20

5 years 2 months ago
Outbrain, which provides an online content marketing platform, raised $160 million by offering 8 million shares at $20, below the range of $24 to $26. Outbrain states that it pioneered the online content recommendation category. Today, its platform enables over 7,000 online prope
Renaissance Capital

Vaccine biotech Icosavax sets terms for $150 million IPO

5 years 2 months ago
Icosavax, a Phase 1 biotech developing vaccines for respiratory diseases, announced terms for its IPO on Thursday.The Seattle, WA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Icosava
Renaissance Capital

Rare disease biotech Rallybio sets terms for $81 million IPO

5 years 2 months ago
Rallybio, a Phase 1/2 biotech developing antibody therapies for rare diseases, announced terms for its IPO on Thursday.The New Haven, CT-based company plans to raise $81 million by offering 5.8 million shares at a price range of $13 to $15. At the midpoint of the proposed range,
Renaissance Capital
Checked
26 minutes 31 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed